JP2020528454A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528454A5
JP2020528454A5 JP2020524721A JP2020524721A JP2020528454A5 JP 2020528454 A5 JP2020528454 A5 JP 2020528454A5 JP 2020524721 A JP2020524721 A JP 2020524721A JP 2020524721 A JP2020524721 A JP 2020524721A JP 2020528454 A5 JP2020528454 A5 JP 2020528454A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524721A
Other languages
English (en)
Japanese (ja)
Other versions
JP7237962B2 (ja
JP2020528454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042573 external-priority patent/WO2019018455A1/en
Publication of JP2020528454A publication Critical patent/JP2020528454A/ja
Publication of JP2020528454A5 publication Critical patent/JP2020528454A5/ja
Application granted granted Critical
Publication of JP7237962B2 publication Critical patent/JP7237962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524721A 2017-07-19 2018-07-18 自己免疫性微小血管系障害を治療する方法 Active JP7237962B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762534237P 2017-07-19 2017-07-19
US62/534,237 2017-07-19
PCT/US2018/042573 WO2019018455A1 (en) 2017-07-19 2018-07-18 METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS

Publications (3)

Publication Number Publication Date
JP2020528454A JP2020528454A (ja) 2020-09-24
JP2020528454A5 true JP2020528454A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7237962B2 JP7237962B2 (ja) 2023-03-13

Family

ID=65016682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524721A Active JP7237962B2 (ja) 2017-07-19 2018-07-18 自己免疫性微小血管系障害を治療する方法

Country Status (12)

Country Link
US (2) US11278517B2 (cg-RX-API-DMAC7.html)
EP (2) EP4269397A3 (cg-RX-API-DMAC7.html)
JP (1) JP7237962B2 (cg-RX-API-DMAC7.html)
KR (1) KR102717665B1 (cg-RX-API-DMAC7.html)
CN (1) CN111065389B (cg-RX-API-DMAC7.html)
AU (1) AU2018304208B2 (cg-RX-API-DMAC7.html)
CA (1) CA3069921C (cg-RX-API-DMAC7.html)
ES (1) ES2957742T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231517T1 (cg-RX-API-DMAC7.html)
MX (1) MX2020000625A (cg-RX-API-DMAC7.html)
PL (1) PL3654965T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019018455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306300A (zh) * 2022-01-04 2022-04-12 上海交通大学医学院附属仁济医院 一种香叶木素的用途及其动物模型的建立方法
KR20260010656A (ko) * 2024-07-11 2026-01-21 한국 한의학 연구원 한련초 추출물 유래 화합물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015153648A1 (en) 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Similar Documents

Publication Publication Date Title
Belum et al. The jarisch–herxheimer reaction: Revisited
Hall et al. Wegener granulomatosis in pediatric patients
Murakami et al. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
BR0206160A (pt) Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
HRP20241584T1 (hr) Postupci liječenja sjögrenovog sindroma inhibitorom brutonove tirozin kinaze
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
MA30665B1 (fr) Traitement de maladies rhumatoïdes avec des glucocorticoïdes a liberation retardee.
MA45202A1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
CN112533675A (zh) 通过递送抗OSMRβ抗体治疗皮肤疾病或病症
Al-Hasany et al. Veno-occlusive disease of the liver in Iraq. Nine cases occurring in three Bedouin families
EP1815867A4 (en) COMBINATION PREPARATION FOR THE TREATMENT OF AUTOIMMUNE DISEASE
Fikri Benbrahim et al. Treatment with adalimumab in amyloidosis secondary to rheumatoid arthritis: two case reports
MA33455B1 (fr) Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux
Ferguson et al. Acute mucocutaneous methotrexate toxicity associated with interface dermatitis and numerous eosinophils
HRP20231517T1 (hr) Postupci liječenja autoimunih mikrovaskularnih poremećaja
Lefaan et al. Challenges in the management of oral manifestations in a patient with limited systemic sclerosis
JP2017031144A (ja) 経口用医薬組成物
JP2023508011A5 (cg-RX-API-DMAC7.html)
WO2020044114A3 (en) Methotrexate pharmaceutical composition
MXPA02012232A (es) Preparacion antipiretica concentrada de xilitol.
Henderson et al. Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation
SU552085A1 (ru) Средство дл лечени нарушений свертывающей системы крови при тромбоцитопенических состо ни х различного происхождени и дл стимул ции гемоопоэза "эритрофосфатид"
Kalu et al. Scalding as an unusual cause of pyoderma gangrenosum
Sharma et al. Acute myeloid leukemia in a young male patient with Behçet’s disease presenting with febrile neutropenia